Literature DB >> 24330289

Hemolytic uremic syndrome related to cryptosporidium infection in an immunocompetent child.

Nikoleta Printza1, Evdoxia Sapountzi, John Dotis, Fotios Papachristou.   

Abstract

Hemolytic-uremic syndrome (HUS) is characterized by the clinical and laboratory manifestations of acute renal failure, thrombocytopenia and microangiopathic hemolytic anemia. In children, the majority of cases occur after an infectious diarrhea mainly associated with the serotype Escherichia coli O157:H7. We present a case of a 5-year-old boy with post-diarrhea HUS due to cryptosporidium. The child remained on peritoneal dialysis for 24 days. However, he had a full recovery of his renal function and 6 months later, his overall condition was still very good. This is a particularly interesting case, not only due to the exceptionally rare cause of HUS, that is, the cryptosporidium, but also because of the serious gastroenteritis caused by the cryptosporidium in an immunocompetent child. It seems that in cases of post-diarrhea HUS, apart from E. coli O157:H7, even the rarest causes of gastroenteritis should be investigated.
© 2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.

Entities:  

Keywords:  children; cryptosporidium; hemolytic-uremic syndrome

Mesh:

Year:  2013        PMID: 24330289     DOI: 10.1111/ped.12127

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  2 in total

1.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

2.  Health sequelae of human cryptosporidiosis in industrialised countries: a systematic review.

Authors:  Bethan L Carter; Rachel M Chalmers; Angharad P Davies
Journal:  Parasit Vectors       Date:  2020-09-04       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.